Clicky

News Feeds

HealthFolk's News section is a health news aggregator with a focus on Nigeria, and Africa as a whole.

[Correspondence] ABSORB IV: will the low rate of scaffold thrombosis persist? – Authors' reply

Tags: General

We thank Ruben Tijssen and colleagues for their interest in our work.
  • Stone GW
  • Ellis SG
  • Gori T
  • et al.
Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.